Pharmacokinetics and Pharmacodynamics of Remimazolam for Procedural Sedation in Children and Adolescents.

ABSTRACT:

Background

Remimazolam is not approved for use in pediatric patients. The pharmacokinetics of remimazolam have been reported to be similar to those of adult patients after scaling for body size. This article reports on the pharmacokinetics and pharmacodynamics of pediatric patients aged 6 to 18 yr and a subsequent model-based optimization of the used dosing regimen.

Methods

Thirty-one patients were included in the trial and stratified across four treatment arms: bolus administration, infusion, bolus plus fentanyl, or infusion plus fentanyl. The University of Michigan (Ann Arbor, Michigan) Sedation Scale (UMSS) was used to assess the depth of sedation. Blood samples were drawn to measure the concentrations of remimazolam and its metabolite CNS7054. Population pharmacokinetic

SUBMITTER: Colin PJ 

PROVIDER: S-EPMC12227205 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature